<p>Insilico’s new program combines AI, circular mRNA and in vivo T-cell engineering to target early cellular drivers of age-related disease. Insilico Medicine has launched a research program aimed at turning a patient’s own immune cells against cellular drivers of age-related disease, using generative </p>